Medtecs International Corporation Limited (9103.TW)
TWD 6.1
(-1.45%)
TWD 6.1
(-1.45%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.24 Million USD | -32.74% |
| 2022 | 3.33 Million USD | -42.41% |
| 2021 | 5.79 Million USD | 71.03% |
| 2020 | 3.38 Million USD | -64.1% |
| 2019 | 9.43 Million USD | 59.53% |
| 2018 | 5.91 Million USD | 261.87% |
| 2017 | 1.63 Million USD | 1427.1% |
| 2016 | 107 Thousand USD | -95.09% |
| 2015 | 2.18 Million USD | -48.99% |
| 2014 | 4.27 Million USD | -44.23% |
| 2013 | 7.66 Million USD | -25.13% |
| 2012 | 10.24 Million USD | -6.3% |
| 2011 | 10.92 Million USD | -22.61% |
| 2010 | 14.12 Million USD | -20.98% |
| 2009 | 17.87 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - USD | 0.0% |
| 2023 Q4 | 2.24 Million USD | -29.44% |
| 2023 FY | 2.24 Million USD | -32.74% |
| 2023 Q2 | 3.17 Million USD | -4.68% |
| 2022 FY | 3.33 Million USD | -42.41% |
| 2022 Q4 | 3.33 Million USD | -85.02% |
| 2022 Q2 | 22.26 Million USD | 284.41% |
| 2021 Q4 | 5.79 Million USD | 83.14% |
| 2021 FY | 5.79 Million USD | 71.03% |
| 2021 Q2 | 3.16 Million USD | -6.62% |
| 2020 FY | 3.38 Million USD | -64.1% |
| 2020 Q4 | 3.38 Million USD | -34.63% |
| 2020 Q2 | 5.18 Million USD | -45.09% |
| 2019 FY | 9.43 Million USD | 59.53% |
| 2019 Q4 | 9.43 Million USD | 70.27% |
| 2019 Q2 | 5.54 Million USD | -6.31% |
| 2018 Q2 | 6.22 Million USD | 280.84% |
| 2018 Q4 | 5.91 Million USD | -4.98% |
| 2018 FY | 5.91 Million USD | 261.87% |
| 2017 Q2 | 1.97 Million USD | 1744.86% |
| 2017 Q4 | 1.63 Million USD | -17.22% |
| 2017 FY | 1.63 Million USD | 1427.1% |
| 2016 Q4 | 107 Thousand USD | -94.49% |
| 2016 FY | 107 Thousand USD | -95.09% |
| 2016 Q2 | 1.94 Million USD | -11.0% |
| 2015 Q2 | 4.24 Million USD | -0.7% |
| 2015 FY | 2.18 Million USD | -48.99% |
| 2015 Q4 | 2.18 Million USD | -48.63% |
| 2014 FY | 4.27 Million USD | -44.23% |
| 2014 Q4 | 4.27 Million USD | -25.74% |
| 2014 Q2 | 5.75 Million USD | -24.9% |
| 2013 FY | 7.66 Million USD | -25.13% |
| 2013 Q4 | 7.66 Million USD | -23.15% |
| 2013 Q2 | 9.97 Million USD | -2.57% |
| 2012 FY | 10.24 Million USD | -6.3% |
| 2012 Q4 | 10.24 Million USD | -0.55% |
| 2012 Q2 | 10.29 Million USD | -5.78% |
| 2011 FY | 10.92 Million USD | -22.61% |
| 2011 Q2 | 13.59 Million USD | -3.76% |
| 2011 Q4 | 10.92 Million USD | -19.59% |
| 2010 Q2 | - USD | -100.0% |
| 2010 FY | 14.12 Million USD | -20.98% |
| 2010 Q4 | 14.12 Million USD | 0.0% |
| 2009 Q2 | 23.57 Million USD | 0.0% |
| 2009 Q4 | 17.87 Million USD | -24.2% |
| 2009 FY | 17.87 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 12.56 Million TWD | 82.152% |
| Maxigen Biotech Inc. | - TWD | -Infinity% |
| SciVision Biotech Inc. | 346.69 Million TWD | 99.353% |
| Bionime Corporation | 1.69 Billion TWD | 99.868% |
| Pegavision Corporation | 365.09 Million TWD | 99.386% |
| Visco Vision Inc. | 848.86 Million TWD | 99.736% |